



Clinical Trial for Lymphoma

Eligibility Criteria

LYM 28: Brief Duration CNOP (or CVP) + Rituximab Followed by Maintenance Rituximab, in Elderly/Poor Performance Status Patients with Aggressive B-Cell Lymphoma

Inclusion Criteria

- Patient has histologically documented large B-cell, CD-20 positive non-Hodgkin's lymphoma
- Disease is clinical stage I, II, III, or IV by the Ann Arbor Staging Criteria
- Patient has not has previous treatment
- ECOG performance status of 0, 1, or 2
- Patient is ≥ 70 years of age.
- Patients that are < 70 years of age are eligible if one or more of the following are met:
 - ECOG performance status is 2
 - Ineligible for anthracycline therapy due to cardiac compromise
 - Poor candidate for 6-8 courses of CHOP chemotherapy due to coexistent medical problems
- Laboratory criteria include the following (laboratory tests must be within 7 days of entry)
 - $WBC \geq 3,000/uL?$
 - $Platelets \geq 100,000/uL?$
 - $Bilirubin \leq 1.5mg/dL?$
 - $Serum\ creatinine \leq 2.0mg/dL?$
- Patient has given informed consent and is accessible for treatment and follow-up

Exclusion Criteria

- Central nervous system involvement with lymphoma (either parenchymal or meningeal)
- Coexistent active malignancies or invasive malignancies treated within five years
- Active infection precluding the use of combination chemotherapy
- Patient had HIV
- Patient is pregnant or lactating
- Patient has known hypersensitivity to *E. coli* derived proteins, pegfilgrastim, or filgrastim